European Commission accepts commitments by Aspen to reduce prices for six off-patent cancer medicines by 73%

 

European Commission accepts commitments by Aspen to reduce prices for six off-patent cancer medicines by 73%

 

Following commitments accepted by the Commission to resolve its abuse of dominance investigation under Article 102 TFEU, Aspen will reduce its prices across Europe for the six cancer medicines by, on average, 73%.

The reductions are on average below 2012 prices before the increases started.

The outcome in this case is consistent with the Commission's Pharmaceutical Strategy for Europe.  This patient-centred strategy seeks to safeguard access to medicines whilst at the same time promoting competition.

This case is one of many similar investigations in Europe in the pharmaceutical sector. It shows that the competition authorities are ready and willing to engage with the vexed question of excess pricing.  https://ec.europa.eu/commission/presscorner/detail/en/ip_21_524